Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.80 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.80 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.80 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.80 |
| ▸ | NQO2 | P16083 | 5/20 | 0.80 |
| ▸ | TTR | P02766 | 4/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.80 |
| ▸ | ABL1 | P00519 | 4/20 | 0.80 |
| ▸ | BCR | P11274 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.80 |
| ▸ | NPC1 | O15118 | 2/20 | 0.80 |
| ▸ | GAA | P10253 | 2/20 | 0.80 |
| ▸ | RAB9A | P51151 | 2/20 | 0.80 |
| ▸ | GFER | P55789 | 2/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pterostilbene SCHEMBL28222684 | 0.89 | CYP1A1 (1.00) | PTGS2ALOX5CYP1A1CYP1B1KDM4E | |
| Pterostilbene SCHEMBL3545782 | 0.89 | CYP1A1 (1.00) | PTGS2ALOX5CYP1A1CYP1B1KDM4E | |
| Pterostilbene SCHEMBL563218 | 0.89 | CYP1A1 (1.00) | PTGS2ALOX5CYP1A1CYP1B1KDM4E | |
| Pterostilbene SCHEMBL20063 | 0.89 | CYP1A1 (1.00) | PTGS2ALOX5CYP1A1CYP1B1KDM4E | |
| SCHEMBL562336 | 0.87 | CYP1A1 (1.00) | PTGS2ALOX5CYP1A1CYP1B1KDM4E | |
| SCHEMBL10312395 | 0.87 | RELA (0.68) | PTGS2ALOX5CYP1A1CYP1B1KDM4E | |
| SCHEMBL12535856 | 0.87 | PTGS2 (0.78) | PTGS2ALOX5CYP1A1CYP1B1KDM4E | |
| SCHEMBL562335 | 0.87 | CYP1A1 (1.00) | PTGS2ALOX5CYP1A1CYP1B1KDM4E | |
| SCHEMBL30475363 | 0.87 | CYP1A1 (1.00) | PTGS2ALOX5CYP1A1CYP1B1KDM4E | |
| SCHEMBL12307322 | 0.84 | PTGS2 (0.79) | PTGS2ALOX5CYP1A1CYP1B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-2531196-B1 | PTEROSTILBENE COCRYSTALS | LAURUS LABS LTD (IN) | 2018-04-18 | — | — | EP | disclosed |
| US-9266813-B2 | Stilbenoid compound as inhibitor for squamous carcinoma and hepatoma and uses thereof | CHINA MEDICAL UNIVERSITY (TW) | 2016-02-23 | — | — | US | disclosed |
| US-9187591-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-11-17 | — | — | US | disclosed |
| US-9127115-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-09-08 | — | — | US | disclosed |
| US-9051414-B1 | Polyphenols and high-performance resins from syringaldehyde | The United States of America as Represented by the Secretary of he Navy (US) | 2015-06-09 | — | — | US | disclosed |
| US-9018314-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-04-28 | — | — | US | disclosed |
| US-8993688-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993689-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2015023811-A2 | COMPOSITIONS AND METHODS FOR IDENTIFYING LATENTLY INFECTED CELLS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-02-19 | — | — | WO | disclosed |
| US-8921614-B1 | Selective deoxygenation of hydroxybenzaldehydes | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140303241-A1 | STILBENOID COMPOUND AS INHIBITOR FOR SQUAMOUS CARCINOMA AND HEPATOMA AND USES THEREOF | ANNCARE BIO-TECH CENTER INC. (TW) | 2014-10-09 | — | — | US | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | KENT STATE UNIVERSITY (US) | 2011-06-02 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303241-A1 | STILBENOID COMPOUND AS INHIBITOR FOR SQUAMOUS CARCINOMA AND HEPATOMA AND USES THEREOF | HDGF, HCCS, HAVCR2 | PTGS2 1437/4885ALOX5 2350/4885CYP1A1 3011/4885 |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | TGFB1, VHL, TMSB10 | PTGS2 62/4885ALOX5 247/4885CYP1A1 874/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | PTGS2 2946/4885ALOX5 977/4885CYP1A1 3467/4885 |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | TKT, HAAO, TTPA | PTGS2 2030/4885ALOX5 734/4885CYP1A1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.